Table 2.
Patient characteristics for 6 AML patients followed longitudinally after transplantation
| Patient | Patient sex | Donor sex | Patient age | FAB | Conditioning regimen | Graft | Donor | cGVHD |
|---|---|---|---|---|---|---|---|---|
| 1 | M | F | 44 | M2 | FTBI/CY | PB | URD | Y |
| 2 | M | F | 65 | M2 | TLI/ATG | PB | URD | Y |
| 3 | M | F | 64 | M2 | TLI/ATG | PB | URD | Y |
| 4 | M | M | 40 | M5 | FTBI/VP16 | PB | SIBL | Y |
| 5 | M | M | 57 | M6 | TLI/ATG | PB | URD | Y |
| 6 | M | M | 56 | NOS | BU/VP16/CY | PB | SIBL | Y |
Six AML patients were followed longitudinally for detection and development of H-Y, NuSAP1, and CHAF1b antibodies and IgG levels.
FTBI indicates fractionated total body irradiation; CY, cyclophosphamide; TLI, total lymphoid irradiation; ATG, anti-thymoglobulin; PB, peripheral blood; URD, unrelated donor; and SIBL, sibling.